Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank36
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P36
Within normal range
vs 3Y Ago
-0.3x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2024-9.41%
202311.10%
202248.56%
202128.04%
202023.65%
2019-24.23%
2018-26.46%
2017-1.23%
2016-19.15%
201512.68%